Purpose: Analysis of ctDNA may enable early identification of patients likely to relapse, presenting an opportunity for early interventions and improved outcomes. Tumor-naïve plasma-only approaches for minimal residual disease (MRD) assessment accelerate turnaround time, enabling rapid treatment decisions and ongoing surveillance. Experimental Design: Plasma samples were obtained from 80 study participants with stage II or III colorectal cancer selected from CIRCULATE-Japan GALAXY. MRD status was assessed using a tumor-naïve ctDNA assay (xM) that integrates methylation and genomic variant data, delivering a binary call. MRD was assessed at 4 weeks postsurgery [landmark time point (LMT)] using methylation and genomic variant data and longitudinally (median, 22.1 months) using only methylation data. Results: At LMT, 69/80 study participants were evaluable (36 recurrent; 33 nonrecurrent). Of recurrent study participants, 22/36 had detectable ctDNA (MRD-positive) at LMT and 29/33 nonrecurrent study participants had undetectable ctDNA (MRD-negative), yielding a clinical sensitivity of 61.1% and specificity of 87.9%. Additionally, 74 study participants were evaluable for longitudinal performance with a clinical sensitivity of 83.3% and specificity of 89.5%. The median lead time from the first MRD-positive result to recurrence was 4.77 months overall, and 5.30 months for study participants with no adjuvant treatment. At 12 weeks postsurgery, MRD status strongly correlated with disease-free survival (adjusted HR, 9.69), outperforming carcinoembryonic antigen correlation (HR, 2.13). Conclusions: This tumor-naïve MRD assay demonstrated clinically meaningful performance at LMT and longitudinally, accurately predicting clinical recurrence. MRD status was a stronger prognostic biomarker for disease-free survival compared with standard-of-care carcinoembryonic antigen.
PURPOSE: FOLFIRINOX (FFX) and gemcitabine + nab-paclitaxel (GnP) are the most commonly administered first-line (1L) regimens for advanced, nonresectable, pancreatic ductal adenocarcinoma (PDAC). In the absence of biomarkers to predict response, clinical covariates such as age and performance status are often used by clinicians to select optimal treatment regimens. Purity independent subtyping of tumors (PurIST) is a molecular subtyping algorithm that classifies tumors as classical or basal. The current study was designed to validate PurIST as a prognostic biomarker for patients receiving 1L FFX and as a predictive biomarker for patients more likely to benefit from FFX versus GnP. PATIENTS AND METHODS: This is a prospectively designed, retrospective study using a real-world data set of 931 patients with advanced PDAC, treated with either 1L FFX or GnP, and designed to demonstrate associations of PurIST subtypes with clinical outcomes. The primary end point was overall survival (OS) in classical versus basal patients treated with 1L FFX, while the secondary end point was OS in classical patients—with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1—to compare 1L FFX versus GnP. RESULTS: Within the cohort of patients receiving 1L FFX (n = 536), basal subtype patients had a median OS of 7 months compared with classical subtype patients with a median OS of 11.8 months (hazard ratio [HR], 1.86 [95% CI, 1.49 to 2.33]; P < .001). In an analysis restricted to patients with classical subtype and ECOG PS of 0 or 1 (n = 311), there was a 33% relative risk reduction of death in patients treated with FFX compared with GnP, adjusting for age and ECOG PS (HR, 0.67 [95% CI, 0.48 to 0.94]; P < .009), with no comparable risk reduction in basal patients (subtype-treatment interaction, P = .002). CONCLUSION: Patients with PDAC of the PurIST classical subtype showed a significant OS benefit when treated with FFX as 1L versus GnP.
Purpose: Resection of liver metastases improves survival in patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD), but relapse remains common. Postresection circulating tumor DNA (ctDNA) is a valid prognostic biomarker; however, no data are available regarding the prognostic effect of presurgery ctDNA after upfront chemotherapy. Experimental Design: Patients (N = 116) with initially unresectable mCRC with LLD who underwent resection after upfront chemotherapy were included. Patients were sequenced with a tumor-naïve ctDNA-based minimal residual disease (MRD) assay at baseline (before chemotherapy), before surgery, and after surgery. Results: Presurgery ctDNA status was not significantly associated with relapse-free survival (RFS). However, exploratory analyses demonstrated that a ≥50% reduction in variant allele frequency from baseline to before surgery was independently associated with improved RFS (median RFS: 21.0 vs. 9.8 months; HR: 2.19; P = 0.014), aligned with multivariate analysis (P = 0.022). Postsurgery ctDNA positivity was strongly predictive of recurrence (HR: 6.66; P < 0.001), with 100% specificity and 56.4% sensitivity. ctDNA dynamics from before to after surgery further stratified recurrence risk, regardless of adjuvant chemotherapy status. ctDNA dynamics from before to after surgery further stratified recurrence risk. Quantitative ctDNA measures (predicted tumor fragments per million) also correlated with RFS. Conclusions: Use of a tumor-naïve MRD assay increased the accuracy of detecting ctDNA after chemotherapy treatment, when a significant drop of ctDNA amount is expected compared with tests routinely used in metastatic disease. Presurgery ctDNA dynamics were prognostic with respect to RFS and may help stratify patients’ prognosis prior to resection, potentially informing personalized treatment decisions.
PURPOSE: Real-world data from electronic health records and next-generation sequencing are used to study treatment effectiveness in molecularly refined patient populations. Incomplete mortality data can overestimate survival rates in these studies. The National Death Index (NDI) is the gold standard for mortality data in the United States, but limited accessibility and reporting delays hinder timely research. External sources can supplement and improve mortality data capture. We evaluated a composite mortality variable against NDI records in a large real-world cohort of patients with advanced cancer. METHODS: Deidentified clinical and molecular data from patients with advanced solid tumors were linked with third-party mortality and claims data sets using deterministic tokenization. Vital status and death dates were harmonized across sources. Patient identifiers were submitted to NDI; true matches were deidentified and joined for analysis. Performance metrics were calculated using NDI as ground truth. Date agreement was assessed at 0-, ±15-, and ±30-day tolerances. Subgroup analyses and a cumulative case/dynamic control (CC/DC) approach were also performed. RESULTS: Among 17,597 patients, the composite mortality variable demonstrated 82% sensitivity and 95% specificity against NDI. The positive predictive value was 96%, and the negative predictive value was 77%. Exact date agreement was 86%, increasing to 94% within a ±15-day tolerance and 96% within a ±30-day tolerance. Incorporating third-party data substantially improved the sensitivity from 17% to 82%. With the CC/DC approach, the sensitivity was 96% at 6 months, 97% at 12 months, and 98% at 24 months, with specificity above 98% across these time frames. CONCLUSION: The composite mortality variable is a robust and reliable end point for real-world evidence analyses with high accuracy for identified deaths and appropriate censoring of patients lost to follow-up.